Brief: Vicore says their C21 Treatment Reduces Long-Term Lung Injury After Covid-19

Vicore Pharma Holding AB

02/11/2021 07:19

Nov 2 (Reuters) - Vicore Pharma Holding AB  VICOR.ST :
    * VICORE'S C21 REDUCES LONG-TERM LUNG INJURY AFTER COVID-19
IN THE
ATTRACT PHASE 2 EXTENSION STUDY
    * RESULTS SHOWED NEARLY 50% REDUCTION IN LUNG INJURY IN C21
GROUP
COMPARED PLACEBO GROUP
    * SAYS POSITIVE FINDINGS TOGETHER WITH PREVIOUS CLINICAL
RESULTS(1
)SUGGEST THAT C21 COULD ACCELERATE RECOVERY

Source text for Eikon:  ID:nWkr8zd6xC 
Further company coverage:  VICOR.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))